Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anaphylaxis
Pharma
ARS inks ex-US licensing pact for Neffy worth up to $465M
ARS will receive up to $465 million in a new licensing pact with ALK-Abelló to sell its epinephrine nasal spray Neffy in certain ex-U.S. territories.
Fraiser Kansteiner
Nov 11, 2024 9:44am
FDA accepts ARS' filing for nasal spray EpiPen rival for review
Oct 25, 2022 10:27am
Bryn advances anaphylaxis spray after completing pivotal trial
Sep 19, 2022 7:00am
ARS inks reverse merger to get epinephrine nasal spray to market
Jul 26, 2022 10:22am
Oral rival to EpiPen clears test on path to pivotal trial
Apr 19, 2022 9:33am
EpiPen rival raises $39M to fund smaller, longer-lasting product
Jan 25, 2022 9:20am
